Home Business Regeneron shares fall after FDA rejects high-dose eye disease treatment

Regeneron shares fall after FDA rejects high-dose eye disease treatment

by news

Regeneron said the rejection was „solely due to an ongoing review of inspection findings at a third-party filler.”
source

Related Posts